Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.
Douglas Adkins, MD
Advertisement
Douglas Adkins, MD, is a professor in the Division of Oncology at Washington University in St. Louis.
Articles by Douglas Adkins, MD
Advertisement
Latest Updated Articles
KEYNOTE-689 Study: Ongoing Follow-Up and Anticipated Overall Survival DataPublished: June 16th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
